Bavarian Nordic A/S (BVNKF)

OTCMKTS · Delayed Price · Currency is USD
24.23
0.00 (0.00%)
Mar 12, 2025, 4:00 PM EST
-0.04%
Market Cap 1.85B
Revenue (ttm) 793.54M
Net Income (ttm) 137.15M
Shares Out n/a
EPS (ttm) 1.75
PE Ratio 13.52
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 108
Average Volume 135
Open 23.37
Previous Close 24.23
Day's Range 23.37 - 24.23
52-Week Range 18.72 - 46.05
Beta 1.68
RSI 50.81
Earnings Date Mar 5, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 1,605
Stock Exchange OTCMKTS
Ticker Symbol BVNKF
Full Company Profile

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK Financial Statements

News

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on

2 days ago - GlobeNewsWire

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization ap...

7 days ago - GlobeNewsWire

Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript

Bavarian Nordic A/S (OTCPK:BVNKF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ETCompany ParticipantsRolf Sass Sorensen - Head, Investor...

8 days ago - Seeking Alpha

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manag...

9 days ago - GlobeNewsWire

Bavarian Nordic Publishes Annual Report 2024

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced.

9 days ago - GlobeNewsWire

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunizatio...

13 days ago - GlobeNewsWire

Biological E in strategic pact with Danish co Bavarian Nordic to manufacture Chikungunya vax for global access

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic to manufacture the latter.

16 days ago - The Times of India

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic's chikungunya vacci...

17 days ago - GlobeNewsWire

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...

27 days ago - GlobeNewsWire

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025.

5 weeks ago - GlobeNewsWire

Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reachin...

5 weeks ago - GlobeNewsWire

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopte...

6 weeks ago - GlobeNewsWire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase sha...

6 weeks ago - GlobeNewsWire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase sha...

7 weeks ago - GlobeNewsWire

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decisi...

2 months ago - GlobeNewsWire

Nigeria set to receive 11,200 doses of Mpox vaccine

The doses, manufactured by Bavarian Nordic, have been allocated to affected countries. The post Nigeria set to receive 11,200 doses of Mpox vaccine appeared first on Premium Times Nigeria .

2 months ago - Premium Times Nigeria

Bavarian Nordic Inks Mpox Vaccine Deal With Serum Institute

Bavarian Nordic A/S agreed to a deal with the world’s largest vaccine manufacturer, the Serum Institute of India Pvt, to make the Danish biotech firm’s mpox shot.

3 months ago - BNN Bloomberg

Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

COPENHAGEN, Denmark, December 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN® mpox vaccine with Serum Institute of India Pvt. Ltd. (“SI...

3 months ago - GlobeNewsWire

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding m...

3 months ago - GlobeNewsWire

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management...

3 months ago - GlobeNewsWire

Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program

COPENHAGEN, Denmark, December 11, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decis...

3 months ago - GlobeNewsWire

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding m...

3 months ago - GlobeNewsWire

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 218,750 as a consequence of employees' exe...

3 months ago - GlobeNewsWire

Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025

Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global health policies. Its diversified vaccine portfolio targets smallpox, mpox, rabies, tic...

4 months ago - Seeking Alpha

Bavarian Nordic's Mpox Moment Fades, But Diversification Shines

Bavarian Nordic's mpox vaccine sales have declined post-outbreak, causing reduced revenue and highlighting its reliance on outbreak-driven demand. The company's Travel Health segment demonstrated stre...

4 months ago - Seeking Alpha